Edit

Press contact

EMBL-EBI
Press Office


EMBL-EBI, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK

contactpress@ebi.ac.uk
+44 1223 494369

B cells linked to immunotherapy

Researchers find evidence that B cells may be more important in immunotherapy than previously thought

Using multiplex-immunostaining to characterise B cells. PHOTO: Christine Wagner
Using multiplex-immunostaining to characterise B cells. PHOTO: Christine Wagner

Researchers at EMBL’s European Bioinformatics Institute (EMBL-EBI) and the Medical University of Vienna have found evidence that B cells might play an important role in immunotherapy for melanoma. Currently, immunotherapy is primarily focused on T cells, but the results suggest that B cells could also provide an interesting research avenue.

Immunotherapy is a form of cancer treatment that uses the body’s own immune system to recognise and fight the disease. It comes in a variety of forms, including cancer vaccines, targeted antibodies or tumour-infecting viruses.  Only some cancer patients currently benefit from this kind of therapy.

Immunotherapy – a game changer

In the case of melanoma, which is a particularly aggressive form of skin cancer, established immunotherapies focus on T cells. T cells play an important role in controlling and shaping the immune system and they are able to directly kill cancer cells, while also recruiting other cells into the process.

A recent study published in Nature Communications has shown that, alongside T cells, B cells play a critical role in triggering melanoma-associated inflammation. B cells are a type of white blood cell, which can produce antibodies along with several important messenger molecules. The researchers found that, in the case of melanoma, B cells act almost like a satnav, directing T cells to the tumour via the secretion of such distinct messenger molecules.

A deeper understanding

“Immunotherapy has transformed cancer treatment,” explains Johannes Griss, Researcher at the Medical University of Vienna and EMBL-EBI. “It unleashes T cells so they can fight cancer in a more effective way. For the first time, we found that B cells also play an important part in the process and help T cells find the tumour. The role of B cells in immunotherapy is still largely unknown, but it seems they may have more impact than previously thought.”

During the study, the researchers observed that when B cells were depleted from melanoma patients, the number of T cells and other immune cells dramatically decreased within the tumours as well. In subsequent experiments, the researchers showed that a special subtype of B cells seems to be responsible for guiding T cells and other immune cells to the tumour.

Observing B cells

Interestingly, melanoma cells seem to force B cells to develop into this distinct B cell subtype. Most excitingly, this specific B cell subtype also increased the activating effect of current immune therapies on T cells, and higher numbers of this B cell subtype in tumours before therapy predicted that a patient would respond better to subsequent immunotherapy.

“Further research is required to answer questions such as how melanoma cells modify B cells, what mechanism B cells use to support the activation of T cells, and how we can help these B cells to support current immunotherapies in cancer patients,” concludes Griss.

This post was originally published on EMBL-EBI News.

Tags: Bioinformatics, Cancer, Computational biology, EMBL-EBI, immunotherapy, Interdisciplinary, melanoma, press release

More from this category

Picture of the week

It’s almost a year since the coronavirus outbreak was declared a pandemic, affecting all our lives. While the virus continues its grip on the world, scientists are understanding it better and better, increasing our knowledge about it and opening up new ways to fight it.

By  Mathias Jäger

3D rendering of a human cell, attacked by a virus.

EMBLetc.

Read the latest Issues of our magazine - EMBLetc.

Looking for past print editions of EMBLetc.? Browse our archive, going back 20 years.

EMBLetc. archive

Newsletter archive

Read past editions of our monthly e-newsletter

For press

Contact the Press Office
Edit